Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimex

Bone Marrow Transplantation

Volumn 24, Issue 10, 1999, Pages 1057-1063

  Rowe, J M ^a,b,f   Rapoport, A P ^a   Ryan, D H ^a   Nilsson, B I ^c   Duerst, R E ^a   Packman, C H ^a   Abboud, C N ^a   Dipersio, J F ^d   Linder, T ^a   Wang, N ^a   Simonsson, B ^e   Liesveld, J L ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Connector Medical ^*  (Sweden)

^d WASHINGTON UNIVERSITY   (United States)

^e UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^f RAMBAM MEDICAL CENTER   (Israel)

Author keywords

Autotransplantation; Chronic myelogenous leukemia; Roquinimex

Indexed keywords

ANAGRELIDE; BUSULFAN; CYCLOPHOSPHAMIDE; HYDROXYUREA; INTERFERON; ROQUINIMEX;

ADOLESCENT; ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD CELL COUNT; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; EDEMA; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; HYPOTHYROIDISM; LEUKEMIA REMISSION; METAPHASE; MYALGIA; NEUTROPHIL; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHILADELPHIA 1 CHROMOSOME; PLEURA EFFUSION; PRIORITY JOURNAL; SCHOOL CHILD; SWEAT GLAND DISEASE;

EID: 0032710365     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702037     Document Type: Article

References (57)

1. Hoyle C, Gray R, Goldman J. Autografting for patients with CML in chronic phase: an update. Br J Haematol 1994; 86: 76-81.
2. O'Brien SG, Goldman JM. Autografting in chronic myeloid leukemia. Blood Rev 1994; 8: 63-68.
3. McGlave PB, DeFabritiis P, Deisseroth A et al. Autologous transplants for chronic myelogenous leukemia: results from eight transplant groups. Lancet 1994; 343: 1486-1488.
4. Carella AM, Celesti L, Lerma E, Dejana A. Stem cell mobilization for autografting in chronic myeloid leukemia. Blood Rev 1998; 11: 154-159.
5. Bhatia R, McGlave PB. Autologous stem cell transplantation for the treatment of chronic myelogenous leukemia. Cancer Treat Res 1997; 77: 357-374.
6. O'Brien SG. Autografting for chronic myeloid leukaemia. Bailliere's Clin Haematol 1997; 10: 369-388.
7. Butturini A, Keating A, Goldman J et al. Autotransplants in chronic myelogenous leukemia: strategies and results. Lancet 1990; 335: 1255-1258.
8. Carella AM, Cunningham I, Lerma E et al. Mobilization and transplantation of Philadelphia-negative peripheral blood progenitor cells early in chronic myelogenous leukemia. J Clin Oncol 1997; 15: 1575-1582.
9. Buckner CD, Stewart P, Clift RA et al. Treatment of blastic transformation of chronic granulocytic leukemia by chemotherapy, total body irradiation and infusion of cryopreserved autologous marrow. Exp Hematol 1978; 6: 96-109.
10. Haines ME, Goldman JM, Worsely AM et al. Chemotherapy and autografting for chronic granulocytic leukemia in transformation: probable prolongation of survival in some patients. Br J Haematol 1984; 58: 711-721.
11. Thomas MR, Robinson WA, Dantas H. Autologous bone marrow transplantation with patients in chronic myelogenous leukemia (CML) in blastic phase. Am J Hematol 1984; 16: 105-112.
12. Karp DD, Parker LM, Binder N. Treatment of the blastic transformation of chronic granulocytic leukemia using high dose BCNU chemotherapy and cryopreserved autologous peripheral blood stem cells. Am J Hematol 1985; 18: 243-249.
13. Vellekoop L, Zander AR, Kantarjian HM. Piperazinedione, total body irradiation and autologous bone marrow transplantation in chronic myelogenous leukemia. J Clin Oncol 1986; 4: 906-911.
14. Reiffers J, Trouett ER, Marit G et al. Autologous blood cell transplantations for chronic granulocytic leukemia and transformation: a report of 47 cases. Br J Haematol 1991; 77: 339-345.
15. Brito-Babapulle F, Apperley JF, Rassool F et al. Complete remission after autografting for chronic myeloid leukemia. Leukemia Res 1987; 11: 1115-1117.
16. Simonsson B, Nilsson B, Hokland P et al. Roquinimex (linomide) vs placebo in patients with AML after ABMT. Bone Marrow Transplant 1997; 19 (Suppl.1): 555 Abstr.
17. Carella AM, Frassoni F, Negrin RS. Autografting in chronic myelogenous leukemia: new questions. Leukemia 1995; 9: 365-369.
18. Coulombel L, Kalousck DK, Eaves CJ et al. Long term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. New Engl J Med 1983; 306: 1493-1498.
19. Carlo-Stella C, Mangoni L, Almici C et al. Autologous transplant of chronic myelogenous leukemia using marrow treated ex vivo with mafosfamide. Bone Marrow Transplant 1994; 14: 425-430.
20. van Dendersen J, ten Hacken P, Berendes P. Antibody recognition of the tumor specific b3-a2 junction of bcr-abl chimeric proteins in Philadelphia-chromosome positive leukemias. Leukemia 1992; 6: 1107-1112.
21. McGlave P, Miller J, Miller W et al. Autologous marrow transplant therapy for CML using marrow treated ex vivo with human recombinant interferon gamma. Blood 1994; 84 (Suppl. 1): 10 (Abstr.).
22. Verfaillie CM, Miller WJ, Boylan K et al. Selection of the nine primitive hematopoietic progenitors in chronic myelogenous leukemia on the basis of HLA-DR antigen expression. Blood 1992; 79: 1003-1010.
23. Talpaz M, Kantarjian H, Liang J et al. Percentage of Philadelphia chromosome-negative and Ph-positive cells found after autologous transplantation of chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose of chemotherapy before collection of autologous cells. Blood 1995; 85: 3257-3263.
24. Szezylik C, Skorski T, Nicolaides NC et al. Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 1991; 253: 562-566.
25. Calabretta B, Sims PB, Valiteri M et al. Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligonucleotides: an in vitro study relevant to bone marrow purging. Proc Natl Acad Sci USA 1991; 88: 2351-2355.
26. 1 leukemia growth in mice by bcr-abl antisense oligonucleotides. Proc Natl Acad Sci USA 1994; 91: 4501-4504.
27. Weisdorf DJ, Nesbid ME, Ramsay NK et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia in remission: prolonged survival associated with acute graft-versus-host disease. J Clin Oncol 1987; 5: 1148-1355.
28. Goldman JM, Gale RP, Horowitz MM. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med 1988; 108: 806-814.
29. Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990; 75: 555-562.
30. Heslop HE, Gottleib D, Bianchi AC et al. In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous marrow transfusion. Blood 1989; 74: 1374-1380.
31. Jones RJ, Vogelsang GB, Hess AD et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989; 1: 754-757.
32. Rowe JM, Nilsson BI, Simonsson B. Treatment of minimal residual disease in myeloid leukemia - the immunotherapeutic options with emphasis on linomide. Leuk Lymphoma 1993; 11: 321-329.
33. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplantations. Blood 1990; 76: 2462-2465.
34. Drobski WR, Keever CA, Roth MS et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood 1993; 82: 2310-2315.
35. Porter DL, Roth MS, McGarigle C et al. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. New Engl J Med 1994; 330: 100-106.
36. Mackinnon S, Barnett L, Heller G et al. Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukaemia. Blood 1994; 83: 3409-3413.
37. van Rhee F, Feng L, Cullis JO et al. Relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation: the case forgiving donor leukocyte transfusions before the onset of hematological relapse. Blood 1994; 83: 3377-3382.
38. Kolb HJ, Schattenberg A, Goldman JM. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86: 2041-2046.
39. Kalland T, Alm G, Stalhandske T. Augmentation of mouse natural killer cell activity by LS2616, a new immunomodulator. J Immunol 1985; 134: 3956-3961.
40. Larsson EL, Joki A, Stalhandske T. Mechanisms of action of the immunomodulator LS2616 on T-cell responses. Int J Immunopharmacol 1987; 9: 425-131.
41. Stalhandske T, Kalland T. Effects of the novel immunomodulator LS2616 on the delayed-type hypersensitivity reaction to Bordetella pertussiss in a rat. Immunopharmacology 1986; 11: 87-92.
42. Ilback NG, Fohlman J, Slorach S et al. Effect of the immunomodulator LS2616 on lymphocyte subpopulations in murine Coxsackie virus B3 myocarditis. J Immunol 1989; 142: 3225-3228.
43. Bengtsson M, Simonsson B, Carlsson K et al. Stimulation of NK cell. T-cell and monocyte functions by the novel immunomodulator Linomite after autologous bone marrow transplantation. A pilot study in patients with acute myeloid leukemia. Transplantation 1992; 53: 882-888.
44. Rowe JM, Ryan D, Dipersio J et al. Autografting in chronic myelogenous leukemia followed by immunotherapy. Stem Cells 1993; 11 (Suppl. 3): 34-42.
45. Hehlmann R, Ansari H, Hasford J et al. Comparative analysis of the impact of risk profile and of drug therapy on survival on CML using Sokal's index and a new score. German Chronic Myeloid Leukemia (CML) Study Group. Br J Haematol 1997; 97: 76-85.
46. Kouides PA, Rowe JM. A dose intensive regimen of cytosine arabinoside and daunorubicin tor chronic myelogenous leukemia in blast crisis. Leukemia Res 1995; 19: 763-770.
47. 1 negative cells in bone marrow and a ten year remission after busulphan hypoplasia. Br J Haematol 1972; 23: 283-288.
48. Goto T, Nishikori M, Arlin Z. et al. Growth characteristics of leukemic and normal hematopoietic cells in Ph+ chronic myelogenous leukemia and effects of intensive treatment. Blood 1982; 59: 793-808.
49. Talpaz M, Kantarjian HM, Kurzrock R et al. Interferon-alpha produces sustained cytogentic responses in chronic myelogenous leukemia Philadelphia chromosome positive patients. Ann Intern Med 1991; 114: 532-538.
50. Hogge DE, Coulombel L, Kalousck DK et al. Non clonal hematopoietic progenitors in a G6PD heterozygote with chronic myelogenous leukemia revealed after long-term marrow culture. Am J Hematol 1987; 24: 389-394.
51. Chang WC, Fugimiyia Y, Casteel N. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. III. Defective interletikin-2 production by T-helper and natural killer cells. Int J Cancer 1989; 43: 591-597.
52. Chang WC, Hsiao MH, Pattengale PK. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, γ-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer target binding and production of natural killer cytotoxic factor. Nat Immun Cell Growth Reg 1991; 10: 57-70.
53. Rowe JM, Ryan DH, Nilsson BI et al. Chronic myelogenous leukemia treated with autologous bone marrow transplantation followed by roquinimex. Blood 1994; 84: 801 (Abstr.).
54. Barrett A, Jiang YZ.Immune responses to chronic myeloid leukemia. Bone Marrow Transplant 1992; 9: 305-311.
55. Goldman JM. Management of chronic myeloid leukaemia. Blood Rev 1994; 10: 21-29.
56. Brito-Babapulle F, Bowcock SJ, Marcus RE et al. Autografting for patients with chronic myeloid leukemia in chronic phase: peripheral blood stem cells may have the finite capacity for maintaining haemopoiesis. Br J Haematol 1989; 73: 76-81.
57. Verfaillie CM, Bhatia R, Miller W et al. BCR/ABL-negative primitive progenitors suitable for transplantation gently selected from the marrow of most early-chronic phase but not accelerated-phase chronic myelogenous leukemia patients. Blood 1996; 87: 4770-4775.